

## Special Issue

# Exploring Neuroinflammation in Central and Peripheral Neuropathic Pain and Related Disorders

### Message from the Guest Editor

Neuropathic pain, driven by central and peripheral nervous system dysfunction, is intricately linked to neuroinflammation and often accompanied by affective (e.g., anxiety and depression) and cognitive (e.g., memory deficits and executive dysfunction) disorders. This Special Issue of *Biomedicines* invites preclinical research and review articles utilizing *in silico*, *in vitro*, and *in vivo* approaches to elucidate neuroinflammatory mechanisms in neuropathic pain and its comorbidities. We welcome studies employing computational modeling (*in silico*), cell-based assays (*in vitro*), and animal models (*in vivo*) to explore molecular pathways, cytokine signaling, and neuroimmune interactions. We encourage contributions leveraging advanced techniques, such as omics-based pathway analyses, neural circuit modeling, or neuroimmune modulation, to address the interplay between neuropathic pain and affective–cognitive impairments. This issue aims to advance preclinical neuroscience, fostering innovative therapeutic strategies for debilitating conditions.

### Guest Editor

Dr. Tahmineh Mokhtari

Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA, USA

### Deadline for manuscript submissions

31 December 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/242548](https://mdpi.com/si/242548)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).